Overview of human obesity and central mechanisms regulating energy homeostasis

被引:44
作者
Crowley, Vivion E. F. [1 ]
机构
[1] St James Hosp, Dept Biochem, Cent Pathol Lab, Dublin 8, Ireland
关键词
D O I
10.1258/acb.2007.007193
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Obesity is now regarded as a global epidemic affecting both adults and children, and is associated with significant morbidity and mortality. Thus the effective management of obesity has become an important clinical focus. Therefore, an understanding of the pathways controlling appetite, satiety and food intake is critical for gaining an insight into the pathogenesis of obesity and also for the development of diagnostic tests and therapeutic agents for use in the clinical management of this condition. Over the last decade or more research using both mouse and human genetic models has elucidated the critical role of the leptin-melanocortin pathway in the hypothalamus, in regulating mammalian energy balance. In tandem with this, a clearer understanding of the regulation of gut-derived hormones and their interaction with the central nervous system has further illuminated the complex interplay between central and peripheral aspects of energy regulation. The obesity epidemic and the expanded knowledge base relating to its aetiopathogenesis have specific implications for clinical biochemistry. In particular, an increase in workload may be expected due to biochemical investigation of obesity and its co-morbidities. Moreover, advice on the in-depth investigation of complex cases of obesity may be sought, including information on newer diagnostic tests, such as serum leptin or molecular genetic analysis. There may also be a substantive role for chemical pathologists in establishing and running clinical obesity services. Finally, clinical biochemistry has a role in research pertaining to obesity and cardiometabolic risk.
引用
收藏
页码:245 / 255
页数:11
相关论文
共 102 条
[1]   Effects of peptide YY[3-36] on short-term food intake in mice are not affected by prevailing plasma ghrelin levels [J].
Adams, SH ;
Won, WB ;
Schonhoff, SE ;
Leiter, AB ;
Paterniti, JR .
ENDOCRINOLOGY, 2004, 145 (11) :4967-4975
[2]   Leptin [J].
Ahima, RS ;
Flier, JS .
ANNUAL REVIEW OF PHYSIOLOGY, 2000, 62 :413-437
[3]   Prevalence and functionality of paucimorphic and private MC4R mutations in a large, unselected European British population, scanned by meltMADGE [J].
Alharbi, Khalid K. ;
Spanakis, Emmanuel ;
Tan, Karen ;
Smith, Matt J. ;
Aldahmesh, Mohammed A. ;
O'Dell, Sandra D. ;
Sayer, Avan Aihie ;
Lawlor, Debbie A. ;
Ebrahim, Shah ;
Smith, George Davey ;
O'Rahilly, Stephen ;
Farooqi, Sadaf ;
Cooper, Cyrus ;
Phillips, David I. W. ;
Day, Ian N. M. .
HUMAN MUTATION, 2007, 28 (03) :294-302
[4]  
[Anonymous], NICE CLIN GUID 43 OB
[5]   Is rimonabant a safe and effective treatment for obesity? [J].
Aronne, Louis J. .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2007, 3 (05) :388-389
[6]   CHOLECYSTOKININ IS A SATIETY HORMONE IN HUMANS AT PHYSIOLOGICAL POSTPRANDIAL PLASMA-CONCENTRATIONS [J].
BALLINGER, A ;
MCLOUGHLIN, L ;
MEDBAK, S ;
CLARK, M .
CLINICAL SCIENCE, 1995, 89 (04) :375-381
[7]   The role of leptin receptor signaling in feeding and neuroendocrine function [J].
Bates, SH ;
Myers, MG .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2003, 14 (10) :447-452
[8]   Gut hormone PYY3-36 physiologically inhibits food intake [J].
Batterham, RL ;
Cowley, MA ;
Small, CJ ;
Herzog, H ;
Cohen, MA ;
Dakin, CL ;
Wren, AM ;
Brynes, AE ;
Low, MJ ;
Ghatei, MA ;
Cone, RD ;
Bloom, SR .
NATURE, 2002, 418 (6898) :650-654
[9]   Inhibition of food intake in obese subjects by peptide YY3-36 [J].
Batterham, RL ;
Cohen, MA ;
Ellis, SM ;
Le Roux, CW ;
Withers, DJ ;
Frost, GS ;
Ghatei, MA ;
Bloom, SR .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (10) :941-948
[10]   PROOPIOMELANOCORTIN-DERIVED PEPTIDES [J].
BERTAGNA, X .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1994, 23 (03) :467-485